← All trials
NCT01030458
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2010
- Primary completion
- Mar 1, 2012
- Completion date
- Mar 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 183
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Katholieke Universiteit LeuvenLead sponsor
- University of KinshasaCollaborator
- University of LibrevilleCollaborator
- Institute of Cardiology AbidjanCollaborator
- University of NigeriaCollaborator
- University of IlorinCollaborator
- Hospital Aristide Le Dantec, Dakar, SenegalCollaborator
- University of EnuguOverall official - principal investigator
- University of IlorinOverall official - principal investigator
- University of KinshasaStudy chair
- Katholieke Universiteit LeuvenStudy director
- Katholieke Universiteit LeuvenReponsible party - principal investigator
- University of YaoundeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.